Growth Metrics

Innoviva (INVA) Non-Current Assets (2010 - 2026)

Innoviva posted quarterly Non-Current Assets of $1.1 billion for Q1 2026, up 58.24% year-on-year from $672.4 million in Q1 2025, and up 17.22% on a QoQ basis from $907.6 million in Q4 2025.

Innoviva (INVA) has 17 years of Non-Current Assets data on file, last reported at $1.1 billion in Q1 2026.

  • For the quarter ending Q1 2026, Non-Current Assets rose 58.24% year-over-year to $1.1 billion; the trailing twelve-month figure through Mar 2026 stood at $3.3 billion (up 2.58% YoY), and the FY2025 full-year result was $907.6 million, up 21.55% from the prior year.
  • Non-Current Assets for Q1 2026 stood at $1.1 billion, up from $907.6 million in the prior quarter.
  • Across five years, Non-Current Assets topped out at $1.1 billion in Q1 2026 and bottomed at $59.6 million in Q3 2022.
  • The 5-year median for Non-Current Assets is $737.3 million (2022), against an average of $557.1 million.
  • Peak annual rise in Non-Current Assets reached 5746.67% in 2022, while the deepest fall reached 90.27% in 2022.
  • A 5-year view of Non-Current Assets shows it stood at $59.6 million in 2022, then gained by 27.73% to $76.2 million in 2023, then jumped by 880.3% to $746.8 million in 2024, then climbed by 21.55% to $907.6 million in 2025, then rose by 17.22% to $1.1 billion in 2026.
  • The last three Non-Current Assets figures came in at $1.1 billion (Q1 2026), $907.6 million (Q4 2025), and $72.6 million (Q3 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non-Current Assets (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - 4.56 Mn
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - 62,953.78
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn 486.60 Mn
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - 5.83 Mn
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - 30.30 Mn
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn 14.75 Bn
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn 22.66 Bn
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn 910.24 Mn
10 Innoviva 1.60 Bn 992.84 Mn 75.83 Mn 1.06 Bn

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 1.06 Bn
Dec 31, 2025 907.65 Mn
Sep 30, 2025 72.59 Mn
Jun 30, 2025 681.79 Mn
Mar 31, 2025 672.37 Mn
Dec 31, 2024 746.75 Mn
Sep 30, 2024 75.85 Mn
Jun 30, 2024 866.64 Mn
Mar 31, 2024 956.27 Mn
Dec 31, 2023 76.18 Mn
Sep 30, 2023 76.18 Mn
Jun 30, 2023 794.70 Mn
Mar 31, 2023 833.32 Mn
Dec 31, 2022 59.64 Mn
Sep 30, 2022 59.64 Mn
Jun 30, 2022 737.31 Mn
Mar 31, 2022 789.65 Mn
Dec 31, 2021 612.72 Mn
Sep 30, 2021 1.02 Mn
Jun 30, 2021 640.89 Mn
Mar 31, 2021 715.36 Mn
Dec 31, 2020 657.51 Mn
Sep 30, 2020 28.65 Mn
Jun 30, 2020 379.43 Mn
Mar 31, 2020 321.10 Mn
Dec 31, 2019 293.59 Mn
Sep 30, 2019 309.16 Mn
Jun 30, 2019 324.62 Mn
Mar 31, 2019 338.60 Mn
Dec 31, 2018 349.15 Mn
Sep 30, 2018 156.56 Mn
Jun 30, 2018 160.03 Mn
Mar 31, 2018 163.50 Mn
Dec 31, 2017 166.97 Mn
Sep 30, 2017 170.46 Mn
Jun 30, 2017 173.96 Mn
Mar 31, 2017 177.45 Mn
Dec 31, 2016 180.95 Mn
Sep 30, 2016 184.42 Mn
Jun 30, 2016 187.69 Mn
Mar 31, 2016 191.12 Mn
Dec 31, 2015 194.61 Mn
Sep 30, 2015 213.88 Mn
Jun 30, 2015 218.13 Mn
Mar 31, 2015 226.31 Mn
Dec 31, 2014 269.47 Mn
Sep 30, 2014 280.24 Mn
Jun 30, 2014 252.45 Mn
Mar 31, 2014 215.84 Mn
Dec 31, 2013 198.06 Mn
Sep 30, 2013 143.68 Mn
Jun 30, 2013 137.47 Mn
Mar 31, 2013 117.01 Mn
Dec 31, 2012 107.45 Mn
Sep 30, 2012 101.41 Mn
Jun 30, 2012 96.04 Mn
Mar 31, 2012 13.40 Mn
Dec 31, 2011 14.02 Mn
Sep 30, 2011 14.16 Mn
Jun 30, 2011 14.50 Mn
Dec 31, 2010 14.85 Mn